IColocomf
Stool DNA Methylation Detection Kit for Colorectal Cancer
IColocomf is a non-invasive DNA Methylation detection kit for Colorectal Cancer. It detect the methylated SDC2 and TFPI2 genes in intestinal exfoliated cells from human stool samples.
IColocomf makes colorectal cancer screening convenient, fast and precise. It can help people to find colorectal cancer in early stages when it is more treatable. It is approved by the National Medical Products Administration(NMPA) and CE.
The Progression of Colorectal Cancer
The Importance of Early Screening
Colorectal Cancer is a high incidence malignant tumor and can be call as CRC normally we also name it as “lazy cancer”.
It’s not easy to discover and we will possibly miss some warning signals from our body during our every moment.
When people have obvious characteristics of CRC, the so-called five-year survival rate has been less than 12%.
Who's at risk?
Age over 40+
History of colorectal cancer in first-degree relatives
With related symptoms
(such as blood in stool, mucus stool, constipation, diarrhea, thin stool, abdominal pain, etc.)
History of colorectal disease or cancer
（History of any malignancy）
History of precancerous colorectal cancer（Colorectal adenoma, inflammatory bowel disease, colorectal polyps, etc.）
Have a family history of hereditary colon polyps
Unexplained anemia or weight loss
History of chronic appendicitis or appendectomy History of chronic biliary disease or cholecystectomy
The Advantage of IColocomf
Non-invasive
Use stool as sample for detection.
Creative
Unique atomic signal capture technique (AS-CAP) enhance sensitivity for methylation specific qPCR.
Efficient
Results available within 4.5h since sample processing
Odorless & Stable
Cell preservation solution eliminate odor and keep the DNA Stable for more than 15 days.
Accurate
The dual-target panel maintains high sensitivity and specificity of detection of left and right sided colon
Cost effective
More reasonable price than colonoscopy
The Comparison between IColocomf with FIT and Colonoscopy
Method name | Colonoscopy | FIT | IColocomf |
| Sensitivity (CRC) | 75%-95% | 70% | 95.30% |
| Sensitivity (Precancerous lesions) | 76% | 22% | 63.40% |
| Specificity | 89%-91% | 95% | 90.30% |
| Home Sampling | No | Yes | Yes |
| Non-invasive | No | Yes | Yes |
| Dietary restrictions | Yes | No | No |
Kit Components of IColocomf
Stool Collection and Preservation Device
Stool DNA Methylation Detection Kit for Colorectal Cancer (Real-Time PCR)
Stool DNA Extraction Kit
DNA Bisulfite Modification Kit
Testing Procedures
Stool sample collection
Pretreatment and extraction
Bisulfite conversion and purification
qPCR procedure
Analysis and Report
Stool sample collection
Pretreatment and extraction
Bisulfite conversion and purification
qPCR procedure
Analysis and Report
Result Interpretation
It is recommended that a positive result should be followed-up with a structural examination of the colon such as diagnostic colonoscopy.
(Note: “Unde” demonstrates no aberrant methylation is detected.）
Basis for result determination | Result determination | |
| SDC2 | TFPI2 | |
| Positive (Ct≤ 38) | Positive (Ct ≤ 38) | Positive |
| Positive (Ct ≤ 38) | Negative (Ct >38 or Unde) | |
| Negative (Ct >38 or Unde) | Positive (Ct ≤ 38) | |
| negative (Ct >38 or Unde) | negative (Ct >38 or Unde) | Negative |